Innovations for Poverty Action

Authors
Julio Saul Solís Arce
WZB Berlin Social Science Center

Shana Warren
Associate Director, Path-to-Scale Research & Research Scientist

Niccoló Meriggi
International Growth Centre

Alexandra Scacco
WZB Berlin Social Science Center

Nina McMurry
WZB Berlin Social Science Center

Maarten Voors
Wageningen University & Research

Georgiy Syunyaev
Columbia University

Amyn Malik
Yale University Institute for Global Health

Dean Karlan
Northwestern University

Michael Callen
London School of Economics and Political Science

Matthieu Teachout
International Growth Centre

Macartan Humphreys
Columbia University

Mushfiq Mobarak
Yale University

Saad B. Omer
Yale University Institute for Global Health

Andrea Guariso
Trinity College Dublin

Jakob Svensson
Stockholm University

Matthieu Teachout
International Growth Centre

Macartan Humphreys
Columbia University

Saad B. Omer
Yale University Institute for Global Health

Staff
Shana Warren
Research Scientist for Path-to-Scale Research

Samya Rahman
Research Analyst

Gloria Ayesiga Eden
Research Associate

Elliott Collins
Research Economist and Director of Poverty Measurement

Margarita Rosa Cabra Garcia
Senior Research Associate

Sofia Jaramillo
Senior Research Manager

Anthony Kamwesigye
Associate Research Manager

Gisele Manirabaruta

Field Manager

Jean Leodomir Habarimana Mfura
Research and Policy Coordinator

Fatoma Momoh
Senior Field Manager

María Juliana Otalora
Research Analyst

Béchir Wendemi Ouédraogo
Research Associate

Touba Bakary Pare
Senior Field Manager

Melina Platas Izama
New York University Abu Dhabi

Laura Polanco
Research Associate

Sarene Shaked
Research Associate

Achille Mignondo Tchibozo
Research Manager

Michael Callen
London School of Economics and Political Science

Mushfiq Mobarak
Yale University

nature medicine

ARTICLES

OPEN

COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries

Julio S. Solis Arce[1], Shana S. Warren[2], Niccolò F. Meriggi[3], Alexandra Scacco[1], Nina McMurry[1], Maarten Voors[4], Georgiy Syunyaev[1,5,6], Amyn Abdul Malik[7], Samya Aboutajdine[3], Opeyemi Adeojo[8,9], Deborah Anigo[10,11], Alex Armand[12,13], Saher Asad[14], Martin Atyera[15], Britta Augsburg[15], Manisha Awasthi[16], Gloria Eden Ayesiga[15], Antonella Bancalari[15,17,18], Martina Björkman Nyqvist[19], Ekaterina Borisova[5,20], Constantin Manuel Bosancianu[1], Magarita Rosa Cabra Garcia[21], Ali Cheema[14,22], Elliott Collins[2], Filippo Cuccaro[23], Ahsan Zia Farooqi[22], Tatheer Fatima[14], Mattia Fracchia[12,24], Mery Len Galindo Soria[25], Andrea Guariso[26], Ali Hasanain[14], Sofia Jaramillo[25], Sellu Kallon[4,24], Anthony Kamwesigye[15], Arjun Kharel[27], Sarah Kreps[28], Madison Levine[4], Rebecca Littman[29], Mohammad Malik[22], Gisele Manirabaruta[30], Jean Léodomir Habarimana Mfura[30], Fatoma Momoh[31], Alberto Mucauque[3], Imamo Mussa[31], Jean Aime Nsabimana[30], Isaac Obara[8], María Juliana Otálora[25], Béchir Wendemi Ouédraogo[32], Touba Bakary Pare[32], Melina R. Platas[33], Laura Polanco[21], Javaeria Ashraf Qureshi[29], Mariam Raheem[34], Vasudha Ramakrishna[35], Ismail Rendrá[37], Taimur Shah[34], Sarene Eyla Shaked[35], Jacob N. Shapiro[36], Jakob Svensson[37], Ahsan Tariq[22], Achille Mignondo Tchibozo[32], Hamid Ali Tiwana[22], Bhartendu Trivedi[34], Corey Vernot[35], Pedro C. Vicente[12,24], Laurin B. Weissinger[38], Basit Zafar[34,39], Baobao Zhang[36], Dean Karlan[1,40], Michael Callen[41], Matthieu Teachout[3], Macartan Humphreys[1,6], Ahmed Mushfiq Mobarak[42] and Saad B. Omer[7]

Widespread acceptance of COVID-19 vaccines is crucial for achieving sufficient immunization coverage to end the global pandemic, yet few studies have investigated COVID-19 vaccination attitudes in lower-income countries, where large-scale vaccination is just beginning. We analyze COVID-19 vaccine acceptance across 15 survey samples covering 10 low- and middle-income countries (LMICs) in Asia, Africa and South America, Russia (an upper-middle-income country) and the United States, including a total of 44,260 individuals. We find considerably higher willingness to take a COVID-19 vaccine in our LMIC samples (mean 80.3%; median 78%; range 30.3 percentage points) compared with the United States (mean 64.6%) and Russia (mean 30.4%). Vaccine acceptance in LMICs is primarily explained by an interest in personal protection against COVID-19, while concern about side effects is the most common reason for hesitancy. Health workers are the most trusted sources of guidance about COVID-19 vaccines. Evidence from this sample of LMICs suggests that prioritizing vaccine distribution to the Global South should yield high returns in advancing global immunization coverage. Vaccination campaigns should focus on translating the high levels of stated acceptance into actual uptake. Messages highlighting vaccine efficacy and safety, delivered by healthcare workers, could be effective for addressing any remaining hesitancy in the analyzed LMICs.

A safe and effective vaccine is a critical tool to control the COVID-19 pandemic. As of 23 June 2021, 23 vaccines had advanced to Stage 3 clinical trials[1] and more than a dozen had been approved in multiple countries[2]. The BNT162b vaccine from Pfizer-BioNTech, for example, has been approved in about 90 countries, while the ChAdOx1 nCoV-19 vaccine from Oxford-AstraZeneca has the most country authorizations at 115[3]. At present, however, global vaccine distribution remains highly unequal, with much of the current supply directed toward high-income countries[4].

Although effective and equitable distribution of COVID-19 vaccines is a key policy priority, ensuring acceptance is just as important. Trust in vaccines as well as the institutions that administer them are key determinants of the success of any vaccination campaign[5]. Several studies have investigated willingness to take a potential COVID-19 vaccine in high-income countries[6–9], and some studies have included middle-income countries[10–11]. Less is known, however, about vaccine acceptance in low-income countries where large-scale vaccination has yet to begin. Understanding the drivers of COVID-19 vaccine acceptance is of global concern, because a lag in vaccination in any country may result in the emergence and spread of new variants that can overcome immunity conferred by vaccines and prior disease[12–17].

A full list of affiliations appears at the end of the paper.

Innovations for Poverty Action

COVID-19 Vaccine Acceptance and Hesitancy in Low- And Middle-Income Countries

Widespread acceptance of COVID-19 vaccines is crucial for achieving sufficient immunization coverage to end the global pandemic, yet few studies have investigated COVID-19 vaccination attitudes in lower-income countries, where large-scale vaccination is just beginning. We analyze COVID-19 vaccine acceptance across 15 survey samples covering 10 low- and middle-income countries (LMICs) in Asia, Africa and South America, Russia (an upper-middle-income country) and the United States, including a total of 44,260 individuals. We find considerably higher willingness to take a COVID-19 vaccine in our LMIC samples (mean 80.3%; median 78%; range 30.1 percentage points) compared with the United States (mean 64.6%) and Russia (mean 30.4%). Vaccine acceptance in LMICs is primarily explained by an interest in personal protection against COVID-19, while concern about side effects is the most common reason for hesitancy. Health workers are the most trusted sources of guidance about COVID-19 vaccines. Evidence from this sample of LMICs suggests that prioritizing vaccine distribution to the Global South should yield high returns in advancing global immunization coverage. Vaccination campaigns should focus on translating the high levels of stated acceptance into actual uptake. Messages highlighting vaccine efficacy and safety, delivered by healthcare workers, could be effective for addressing any remaining hesitancy in the analyzed LMICs.

July 16, 2021